Janssen Sciences Ireland UC clinical trials

A country office of Johnson & Johnson

The registry lists 29 studies whose lead sponsor is Janssen Sciences Ireland UC. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.

Studies

Recruiting first, then most recently updated. Showing 29 of 29. All Johnson & Johnson studies →

• A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingNot yet recruitingNCT07746765

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric StudiesActive, not recruitingNCT02494986Phase 2

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected ParticipantsCompletedNCT00980538Phase 3

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus InfectionCompletedNCT03982186Phase 2

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus InfectionCompletedNCT04129554Phase 2

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)TerminatedNCT04056611Phase 2

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy ParticipantsCompletedNCT02578550Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult ParticipantsCompletedNCT03945539Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)CompletedNCT02662712Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral TabletCompletedNCT02561936Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study of JNJ-73763989 in Healthy Japanese Adult ParticipantsCompletedNCT04002752Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 YearsCompletedNCT00799864Phase 2

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus InfectionCompletedNCT03361956Phase 2

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRVCompletedNCT01281813Phase 3

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.CompletedNCT02387606Phase 2

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected SubjectsCompletedNCT02431247Phase 3

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric ParticipantsNo longer availableNCT04221412

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379CompletedNCT04208399Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically SuppressedCompletedNCT03463369Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 InfectionApproved for marketingNCT03847376

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989CompletedNCT04208386Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) InfectionTerminatedNCT02593851Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRVCompletedNCT01138605Phase 2

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02421211Phase 2

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy ParticipantsCompletedNCT02426632Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose CombinationCompletedNCT02475135Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult ParticipantsCompletedNCT02385071Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)CompletedNCT03111511Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC

• A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult ParticipantsCompletedNCT02398591Phase 1

  Sponsor listed in the registry: Janssen Sciences Ireland UC